Yale Center for the Science of Cannabis and Cannabinoids

Why It Matters

As cannabis potency skyrockets, Yale’s evidence‑based research equips regulators and healthcare providers with the data needed to balance potential medical benefits against emerging neurocognitive and psychiatric risks.

Key Takeaways

• THC potency rose from 4% in 1960s to 35% today.
• Yale Center funds interdisciplinary cannabis research from molecular to behavioral.
• Heavy users show 15% fewer hippocampal synapses, affecting memory.
• Studies use ecological momentary assessment to track real‑time effects on schizophrenia.
• Goal: deliver definitive evidence on both therapeutic benefits and risks.

Summary

The Yale Center for the Science of Cannabis and Cannabinoids was created to generate rigorous, interdisciplinary research on cannabis—from molecular neuroscience to real‑world behavioral studies—and to train the next generation of investigators for the next two decades.

The Center highlights how THC potency has surged, climbing from roughly 4% in the 1960s to 35% today, with some concentrates exceeding 95%. Researchers have documented a 15% reduction in hippocampal synapses among heavy users, linking higher potency to potential memory impairments. Ongoing projects include an ecological momentary assessment (EMA) diary study tracking moment‑to‑moment cannabis use and symptom fluctuations in individuals with schizophrenia.

These findings illustrate the Center’s dual approach: cutting‑edge lab work paired with naturalistic, participant‑driven data collection. By combining synaptic imaging, clinical interviews, and EMA technology, Yale aims to produce synergistic evidence that can clarify both therapeutic potentials and adverse outcomes of modern cannabis products.

The ultimate implication is clear: policymakers, clinicians, parents, and the public will receive high‑quality, actionable data to guide decisions about cannabis regulation, medical use, and harm‑reduction strategies.

Original Description

For more information on the Yale Center for the Science of Cannabis and Cannabinoids or #YaleSchoolOfMedicine, visit: https://medicine.yale.edu/psychiatry/research/clinics-and-programs/center-science-cannabis-cannabinoids.

The Yale Center for the Science of Cannabis and Cannabinoids (YC-SCAN²), established in 2023, was created to advance the understanding of cannabis and its derivatives, often referred to as cannabinoids. This innovative Center is a hub for groundbreaking research, dissemination of information, and education in the field of cannabis and cannabinoid science. Their mission is to conduct comprehensive research on the risks and potential therapeutic applications of cannabis and cannabinoids, and to inform public policy based on our findings. At YC-SCAN², they focus on thorough scientific research and strive to find science-based answers to critical questions concerning the risks and potential medical benefits associated with cannabis and its derivatives. They are also dedicated to translating the knowledge we gain into helpful, practical applications that could enhance patient care and inform public policy. The Center supports pilot projects from Yale-affiliated researchers, aiming to bridge the gap between basic and clinical research. These projects form the foundation for larger funding applications to NIH and other agencies. YC-SCAN² also encourages multidisciplinary studies into the effects of cannabis and cannabinoids, combining molecular neuroscience, genetics, electroencephalography, imaging, and psychopharmacology. We are deeply committed to training the next generation of scientists and clinicians to carry forward this important work in the emerging field of cannabis science.

0:00 YC-SCAN²

1:10 Mission

1:45 Approach

3:19 Where might this research lead?